FDA Accepts New Drug Application for Ralinepag for Pulmonary Arterial Hypertension

United Therapeutics Corporation's New Drug Application (NDA) for ralinepag, an investigational once-daily oral prostacyclin for pulmonary arterial hypertension (PAH), has been accepted by the U.S. FDA. This acceptance initiates the formal review process, with a PDUFA target action date set for June 24, 2027, potentially leading to a new oral treatment option for PAH patients.